PRKG1 (Vector Vector will be determined during the manufacturing process, either pENTR223.1 or pUC,

Length: 2061 Sequence: ATGGGCACCT TGCGGGATTT ACAGTACGCG CTCCAGGAGA AGATCGAGGA GCTGAGGCAG CGGGATGCTC TCATCGACGA GCTGGAGCTG GAGTTGGATC AGAAGGACGA ACTGATCCAG AAGCTGCAGA ACGAGCTGGA CAAGTACCGC TCGGTGATCC GACCAGCCAC CCAGCAGGCG CAGAAGCAGA GCGCGAGCAC CTTGCAGGGC GAGCCGCGCA CCAAGCGGCA GGCGATCTCC GCCGAGCCCA CCGCCTTCGA CATCCAGGAT CTCAGCCATG TGACCCTGCC CTTCTACCCC AAGAGCCCAC AGTCCAAGGA TCTTATAAAG GAAGCTATCC TTGACAATGA CTTTATGAAG AACTTGGAGC TGTCGCAGAT CCAGGAGATT GTGGATTGTA TGTACCCGGT GGAGTATGGC AAGGACAGTT GCATCATCAA AGAAGGAGAC GTGGGGTCAC TGGTGTATGT CATGGAAGAT GGTAAGGTTG AAGTTACAAA AGAAGGTGTG AAGTTGTGTA CCATGGGTCC AGGAAAAGTG TTTGGGGAAT TGGCTATTCT TTACAACTGT ACCCGGACAG CGACCGTCAA GACTCTTGTA AATGTAAAAC TCTGGGCCAT TGATCGACAA TGTTTTCAAA CAATAATGAT GAGGACAGGA CTCATCAAGC ATACCGAGTA TATGGAATTT TTAAAAAGCG TTCCAACATT CCAGAGCCTT CCTGAAGAGA TCCTCAGCAA GCTTGCTGAT GTCCTTGAAG AGACCCACTA TGAAAATGGA GAATATATTA TCAGGCAAGG TGCAAGAGGG GACACCTTCT TTATCATCAG CAAAGGAACG GTAAATGTCA CTCGTGAAGA CTCACCGAGT GAAGACCCAG TCTTTCTTAG AACTTTAGGA AAAGGAGACT GGTTTGGAGA GAAAGCCTTG CAGGGGGAAG ATGTGAGAAC AGCAAACGTA ATTGCTGCAG AAGCTGTAAC CTGCCTTGTG ATTGACAGAG ACTCTTTTAA ACATTTGATT GGAGGGCTGG ATGATGTTTC TAATAAAGCA TATGAAGATG CAGAAGCTAA AGCAAAATAT GAAGCTGAAG CGGCTTTCTT CGCCAACCTG AAGCTGTCTG ATTTCAACAT CATTGATACC CTTGGAGTTG GAGGTTTCGG ACGAGTAGAA CTGGTCCAGT TGAAAAGTGA AGAATCCAAA ACGTTTGCAA TGAAGATTCT CAAGAAACGT CACATTGTGG ACACAAGACA GCAGGAGCAC ATCCGCTCAG AGAAGCAGAT CATGCAGGGG GCTCATTCCG ATTTCATAGT GAGACTGTAC AGAACATTTA AGGACAGCAA ATATTTGTAT ATGTTGATGG AAGCTTGTCT AGGTGGAGAG CTCTGGACCA TTCTCAGGGA TAGAGGTTCG TTTGAAGATT CTACAACCAG ATTTTACACA GCATGTGTGG TAGAAGCTTT TGCCTATCTG CATTCCAAAG GAATCATTTA CAGGGACCTC AAGCCAGAAA ATCTCATCCT AGATCACCGA GGTTATGCCA AACTGGTTGA TTTTGGCTTT GCAAAGAAAA TAGGATTTGG AAAGAAAACA TGGACTTTTT GTGGGACTCC AGAGTATGTA GCCCCAGAGA TCATCCTGAA CAAAGGCCAT GACATTTCAG CCGACTACTG GTCACTGGGA ATCCTAATGT ATGAACTCCT GACTGGCAGC CCACCTTTCT CAGGCCCAGA TCCTATGAAA ACCTATAACA TCATATTGAG GGGGATTGAC ATGATAGAAT TTCCAAAGAA GATTGCCAAA AATGCTGCTA ATTTAATTAA AAAACTATGC AGGGACAATC CATCAGAAAG ATTAGGGAAT TTGAAAAATG GAGTAAAAGA CATTCAAAAG CACAAATGGT TTGAGGGCTT TAACTGGGAA GGCTTAAGAA AAGGTACCTT GACACCTCCT ATAATACCAA GTGTTGCATC ACCCACAGAC ACAAGTAATT TTGACAGTTT CCCTGAGGAC AACGATGAAC CACCACCTGA TGACAACTCA GGATGGGATA TAGACTTCTA Protein function: Serine/threonine protein kinase that acts as key mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smooth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates IRAG1 and inhibits IP3-induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation, decreasing contraction, controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down- regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle. [The UniProt Consortium]